A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of TTI-621 or TTI-622 in combination with daratumumab
hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look
for the highest dose of TTI-621 and TTI-622 that causes few or mild side effects in
participants when given in combination with daratumumab hyaluronidase-fihj. Once the
researchers find the highest safe dose of each study drug, they will further test the
combinations (TTI-621 + daratumumab hyaluronidase-fihj and TTI-622 + daratumumab
hyaluronidase-fihj) in new participants to find out if the combinations are effective in
treating relapsed/refractory multiple myeloma. Researchers think that combining TTI-621 or
TTI-622 with daratumumab hyaluronidase-fihj, a standard treatment for multiple myeloma, may
be an effective treatment approach.